https://pharminent.com/market-access/market-access-intelligence-weekly-digest-june-12-2026/ 2026-06-12T12:22:11Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • June 12, 2026 2026-06-12T12:22:09Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-june-11-2026/ 2026-06-11T22:29:44Z Pharminent en Rare Disease & Gene Therapy Digest • June 11, 2026 2026-06-11T22:29:43Z Blog https://pharminent.com/81810-2/ 2026-06-11T22:26:29Z Pharminent en 2026-06-11T22:17:17Z Blog https://pharminent.com/81804-2/ 2026-06-11T20:41:30Z Pharminent en 2026-06-11T20:05:53Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-11-2026/ 2026-06-11T17:46:29Z Pharminent en Strategic News Watch • June 11, 2026 2026-06-11T17:46:23Z Blog https://pharminent.com/sky-high-parabilis-kailera-ipos-spur-optimism-but-only-for-derisked-biotechs/ 2026-06-11T15:35:00Z Pharminent en Sky-high Parabilis, Kailera IPOs spur optimism--but only for derisked biotechs 2026-06-11T13:44:20Z Blog https://pharminent.com/jj-adds-rare-disease-waiha-to-imaavys-potential-uses/ 2026-06-11T15:35:01Z Pharminent en J&J adds rare disease wAIHA to Imaavy's potential uses 2026-06-11T13:03:57Z Blog https://pharminent.com/novartis-gets-win-for-another-avidity-muscular-dystrophy-aoc/ 2026-06-11T15:35:04Z Pharminent en Novartis gets win for another Avidity muscular dystrophy AOC 2026-06-11T12:04:17Z Blog https://pharminent.com/takedas-4b-tyk2-drug-tops-bristol-myers-sotyktu-in-head-to-head-test/ 2026-06-11T15:39:53Z Pharminent en Takeda's $4B TYK2 drug tops Bristol Myers' Sotyktu in head-to-head test 2026-06-11T11:00:00Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-june-10-2026/ 2026-06-10T22:46:04Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • June 10, 2026 2026-06-10T22:46:01Z Blog https://pharminent.com/81736-2/ 2026-06-11T16:15:23Z Pharminent en 2026-06-10T20:42:15Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-june-10-2026/ 2026-06-10T20:27:20Z Pharminent en Manufacturing Intelligence • Weekly Digest • June 10, 2026 2026-06-10T20:27:16Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-10-2026/ 2026-06-10T18:15:41Z Pharminent en Strategic News Watch • June 10, 2026 2026-06-10T18:15:36Z Blog https://pharminent.com/aquipta-recommended-by-nice-for-acute-migraine-treatment/ 2026-06-10T15:25:19Z Pharminent en Aquipta recommended by NICE for acute migraine treatment 2026-06-10T13:35:05Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-june-9-2026/ 2026-06-10T13:06:02Z Pharminent en Oncology Intelligence Digest • June 9, 2026 2026-06-10T13:05:59Z Blog https://pharminent.com/lilly-wins-new-fda-approval-for-eczema-drug-ebglyss/ 2026-06-10T15:25:24Z Pharminent en Lilly wins new FDA approval for eczema drug Ebglyss 2026-06-10T12:59:56Z Blog https://pharminent.com/discs-fda-meeting-sets-clear-path-for-embattled-rare-blood-disease-drug/ 2026-06-10T15:25:26Z Pharminent en Disc's FDA meeting sets 'clear path' for embattled rare blood disease drug 2026-06-10T12:31:25Z Blog https://pharminent.com/bayers-asundexian-starts-eu-review-for-ischaemic-stroke/ 2026-06-10T15:25:27Z Pharminent en Bayer's asundexian starts EU review for ischaemic stroke 2026-06-10T12:00:43Z Blog https://pharminent.com/abbvies-migraine-drug-cleared-for-migraine-attacks-on-nhs/ 2026-06-10T15:25:29Z Pharminent en AbbVie's migraine drug cleared for migraine attacks on NHS 2026-06-10T10:51:09Z Blog https://pharminent.com/aditxt-and-ignite-announce-merger-plans-with-strategic-partner-2/ 2026-06-10T15:25:30Z Pharminent en Aditxt and Ignite announce merger plans with strategic partner 2026-06-10T10:09:36Z Blog https://pharminent.com/cancer-biotech-parabilis-books-record-ipo-raising-670m/ 2026-06-10T15:25:31Z Pharminent en Cancer biotech Parabilis books record IPO, raising $670m 2026-06-10T09:55:07Z Blog